Browse the evidence

Insulin-lowering dietary strategies (calorie restriction, ketogenic/low-carbohydrate diets, and intermittent fasting) reduce systemic insulin and IGF-1 levels, which attenuates insulin-related growth signaling and reduces metastatic disease burden in preclinical animal models.

For metastatic cancer patients, insulin-lowering diets (like low-carb or intermittent fasting) are safe and feasible adjuncts to standard care. They improve metabolic markers (insulin, glucose) and may help control disease, but they are not yet proven to extend survival. Consult your oncology team to implement these strategies safely, ensuring they do not exacerbate weight loss or cachexia.

GLP-1 receptor agonists (GLP-1 RAs) show promise as gerotherapeutic drugs by protecting against aging-related risk factors such as oxidative stress, cellular senescence, and inflammation, and may reverse brain aging and prevent sarcopenic obesity, although lifespan extension in humans is not yet reported.

If you are considering GLP-1 RAs for weight loss, discuss with your doctor their potential anti-aging benefits, such as reducing inflammation and protecting against cellular senescence. While they are not yet proven to extend lifespan in humans, they may offer significant healthspan benefits.

In individuals with type 2 diabetes and existing complications, a 5-day prolonged fasting-mimicking diet followed by a glucose load significantly reduces cellular resistance to dicarbonyl stress and increases oxidative stress markers, indicating heightened susceptibility to metabolic harm upon refeeding.

If you have Type 2 Diabetes with known complications (like kidney or nerve issues), extreme fasting followed by a large carbohydrate load may stress your cells more than it helps them. While fasting can improve insulin sensitivity in some, it appears to reduce your cells' ability to handle stress in this specific subgroup. Consult your doctor before attempting prolonged fasting, as your body may react with increased oxidative stress rather than metabolic improvement.

Time-restricted eating combined with calorie restriction does not provide significant additional benefits for blood pressure, glucose profile, or lipid profile compared to calorie restriction alone.

Do not expect time-restricted eating to fix your blood pressure, blood sugar, or cholesterol if you are just counting calories. The benefits for these markers are not significantly better than just counting calories alone. Focus on the weight loss aspect of TRE.

Bariatric surgery significantly improves glycemic control (HbA1c reduction) in patients with metabolic syndrome, with effects sustained over 5 years.

For patients with metabolic syndrome and Type 2 Diabetes, bariatric surgery offers significant and sustained improvements in blood sugar control, often superior to medical management alone.

Bariatric surgery significantly improves blood pressure and lipid profiles in patients with and without metabolic syndrome.

Bariatric surgery leads to significant and sustained improvements in blood pressure and lipid profiles, reducing cardiovascular risk.

Activation of SIRT1, SIRT3, and SIRT6 improves glucose metabolism and insulin sensitivity through mechanisms involving AMPK activation, NF-kB inhibition, and regulation of transcription factors like FoxO1 and PGC1α.

While specific SIRT-activating supplements are marketed, the most reliable way to support SIRT activity and metabolic health is through exercise and maintaining metabolic balance. The paper highlights that exercise improves SIRT6-mediated insulin signaling and that SIRT1 activation via AMPK helps glucose tolerance. Focus on consistent physical activity and metabolic health rather than unproven supplements.

SIRTs (particularly SIRT1, SIRT2, SIRT6, and SIRT7) exert anti-inflammatory effects by inhibiting the NF-kB pathway and reducing pro-inflammatory cytokines like TNF-alpha and IL-6.

Chronic inflammation is a risk factor for many diseases. SIRTs help regulate this process. While specific SIRT activators are not yet standard therapy, lifestyle factors that support SIRT activity (like exercise) may help manage inflammatory markers naturally.

Routine screening of serum 25(OH)D levels is not recommended for any population (children, adults, pregnant, obese, dark complexion) in the absence of established clinical indications.

Do not get your vitamin D levels tested unless you have a specific medical condition like hypocalcemia. The guideline states that no specific blood level has been proven to prevent disease, so testing will not change your advice: just take the standard recommended dose.

Sirtuins (SIRTs) are potential therapeutic targets for NAFLD treatment, with SIRT1 playing a key role in regulating lipid metabolism and autophagy.

Sirtuins are being studied as potential drug targets for NAFLD, but no specific sirtuin-activating supplements or drugs are currently recommended for treatment.

Metformin is a common pharmacological insulin sensitization therapy used to treat PCOS, though specific dosing protocols are not detailed in this review excerpt.

Metformin is a standard medication for treating insulin resistance in PCOS. Consult a doctor for appropriate dosing and monitoring.

Serum Anti-Mullerian Hormone (AMH) can be used as an alternative to ultrasound for defining Polycystic Ovarian Morphology (PCOM) in adults, but should not be used as a single test or in adolescents.

In adults, AMH blood tests can help confirm PCOS if ultrasound isn't possible or preferred, but it is never used alone. It is not recommended for adolescents. Discuss with your doctor if it fits your diagnostic pathway.

Gut microbiota dysbiosis, specifically involving Escherichia Coli producing the CIpB protein, may contribute to eating disorder pathology by mimicking satiety hormones and triggering autoimmune reactions.

Current research suggests gut health may play a role in eating disorders, but it is not yet a primary treatment target. Focus on established treatments like nutritional rehabilitation and therapy. Future probiotics or microbiome-targeted therapies may emerge, but are not currently standard care.

Elevated plasma branched-chain amino acid (BCAA) levels contribute to the development of insulin resistance through multiple mechanisms, including mTOR/S6K-mediated inhibition of insulin signaling, inhibition of pyruvate dehydrogenase (PDH), and accumulation of toxic metabolites causing mitochondrial dysfunction.

If you have insulin resistance or Type 2 Diabetes, be mindful of very high intakes of branched-chain amino acids (found in red meat, dairy, and supplements), especially when combined with high-fat meals, as this may worsen insulin sensitivity. Focus on balanced protein intake rather than extreme high-protein or high-fat combinations, and prioritize exercise which helps clear BCAA.

Pharmacological activation of the BCKD complex using agents like BT2 or Sodium Phenylbutyrate (NaPB) accelerates BCAA catabolism, lowers plasma BCAA levels, and improves insulin sensitivity in animal models of obesity and diabetes.

Current research shows that drugs like BT2 and NaPB can fix BCAA metabolism issues in lab animals, improving insulin sensitivity. However, these are not yet approved or proven safe for humans for this purpose. Focus on exercise and balanced nutrition to naturally support BCAA clearance.

Different forms of cell death (apoptosis, necroptosis, pyroptosis) in adipose tissue have distinct inflammatory consequences; necroptosis is highly inflammatory and linked to metabolic dysfunction, while apoptosis may trigger anti-inflammatory macrophage responses.

Not all fat loss is created equal. The way fat cells die matters. Necroptosis (inflammatory cell death) worsens metabolic health, while apoptosis might sometimes trigger a less inflammatory response. Strategies that minimize inflammatory cell death may be metabolically superior.

Aberrant protein posttranslational modifications (PTMs) are central drivers of metabolic diseases including diabetes, obesity, and atherosclerosis, and targeting these modifications offers a viable therapeutic strategy.

Metabolic diseases are driven by complex molecular switches (PTMs) that regulate how your body processes energy. While lifestyle changes are the first line of defense, pharmaceutical interventions targeting these specific molecular pathways (like kinase inhibitors) are increasingly available and effective for managing conditions like diabetes and fatty liver disease when lifestyle changes are insufficient.

Gut microbiota alterations in obesity contribute to chronic low-grade inflammation through increased lipopolysaccharide (LPS) translocation, which triggers immune responses and insulin resistance.

High levels of bacterial toxins (LPS) can leak into your bloodstream if your gut barrier is compromised, causing inflammation and insulin resistance. A diet rich in fiber and fermented foods may support gut barrier integrity.

Astragaloside IV (AS-IV), a saponin in Astragalus, reduces blood glucose and insulin resistance by modulating intestinal microbiota to increase butyric acid and activating PI3K/AKT and AMPK/SIRT1 signaling pathways.

Astragaloside IV (AS-IV), a key compound in Astragalus, may help lower blood sugar and improve insulin sensitivity. It works by changing gut bacteria to produce more butyric acid and by activating specific cellular pathways that help cells use insulin better. This suggests Astragalus may be beneficial for managing T2DM.

Elevated levels of pro-inflammatory adipokines (e.g., leptin, resistin, chemerin, FABP4) and reduced levels of anti-inflammatory adipokines (e.g., adiponectin) drive chronic low-grade inflammation in adipose tissue during obesity, contributing to insulin resistance and metabolic disorders.

Obesity involves complex hormonal signaling from fat tissue that promotes inflammation and insulin resistance. While this review focuses on mechanisms rather than direct lifestyle advice, it underscores that metabolic health is influenced by the biochemical environment of fat tissue, not just energy balance. Targeting these inflammatory pathways (e.g., through weight loss or specific medical interventions) may help mitigate metabolic risks.

Leptin acts as a pro-inflammatory cytokine in adipose tissue by promoting macrophage infiltration and activation via JAK/STAT, MAPK, and PI3K pathways, contributing to local inflammation and lipid accumulation.

High levels of leptin in obesity do more than affect hunger; they actively promote inflammation in fat tissue by attracting and activating immune cells (macrophages). This inflammatory state contributes to insulin resistance and other metabolic issues.

Resistin promotes inflammation and insulin resistance by binding to TLR4 and activating NF-kB, JNK, and p38 MAPK pathways in macrophages and hypothalamic cells.

Resistin, a protein elevated in obesity, contributes to inflammation and insulin resistance by activating specific immune pathways (TLR4/NF-kB). This highlights the complex interplay between fat tissue, immune cells, and metabolic health.

Cold exposure activates the beta-3 adrenergic receptor system, leading to UCP1 upregulation and non-shivering thermogenesis, although human response varies significantly compared to rodents.

Cold exposure can activate brown fat via the beta-3 adrenergic system, but human response is highly variable and often weaker than in mice. While you can try cold showers or lower temperatures, do not rely on it as a primary weight loss strategy. Diet and exercise are more reliable and practical methods to increase metabolic rate.

Certain pharmaceutical drugs (ACE inhibitors, statins, mTOR inhibitors) and lifestyle interventions (exercise) can increase circulating Klotho levels, potentially offering therapeutic benefits for age-related diseases.

Regular physical activity and adherence to prescribed medications for blood pressure, cholesterol, or metabolic health may naturally support higher Klotho levels. This suggests that standard health maintenance practices contribute to longevity mechanisms.